Massive hemoptysis is a serious complication leading to death in lung cancer patients. To investigate whether fatal hemoptysis is associated with concurrent chemoradiation therapy (CCRT), the authors retrospectively analyzed risk factors for fatal hemoptysis after CCRT. 
Introduction
Chemoradiation therapy has been the mainstay of treatment in patients with locally advanced non-small cell lung carcinoma (NSCLC), due to its superiority over radiation therapy alone. [1] [2] [3] [4] Chemoradiation therapy can be administered patients sequentially or concurrently. A number of studies have found that concurrent chemoradiation therapy (CCRT) appears to outweigh sequential therapy in view of treatment effectiveness. 5, 6 It has been shown that CCRT can be considered tolerable under the maximum tolerated dose. 7 We have defined fatal hemoptysis as a massive hemoptysis resulting in death of the patient. No study has been conducted to investigate the risk factors associated with fatal hemoptysis following CCRT in locally advanced NSCLC patients.
From the unpredictable perspective of fatal hemoptysis, we decided to perform a retrospective investigation. We observed 12 cases of fatal hemoptysis during a 3-year period in our hospital, which led to death after CCRT in patients with locally advanced NSCLC. We analyzed risk factors associated with fatal hemoptysis after CCRT in NSCLC patients.
Materials and Methods
A retrospective review of patients diagnosed as having NSCLC and treated with CCRT was carried out at a single referral hospital. We conducted a multivariate analysis with a logistic regression following an adjustment for clinical factors. A p value ＜0.05 was assumed to be statistically significant.
Results
Out of the 150 patients, 12 (8.0%) died of fatal hemoptysis.
There were 10 men and 2 women, and their median age at diagnosis was 62 years. All except 3 patients had central and squamous tumors. The major symptoms prior to fatal hemoptysis were infection-related fever (n=6), dyspnea (n=5), and chest pain (n=1). All patients had radiation pneumonitis and/or radiation fibrosis. A Bronchoscopy performed prior to fatal hemoptysis demonstrated radiation PS, performance status; CTX/con, chemotherapy/consolidation; RT dose, dose of radiation therapy; Interval, the interval between fatal hemoptysis and completion of CCRT; Symptom, the last symptom before fatal hemoptysis; Survival, the survival period after pathologic confirmation; F, female; M, male; SQC, squamous cell carcinoma; ADC, adenocarcinoma; NSCLC, non-small cell lung carcinoma; PR, partial response; SD, stable disease; PD, progressive disease; GP, gemcitabine＋cisplatin; TP, paclitaxel＋cisplatin; DP, docetaxel＋cisplatin; RP, radiation pneumonitis. Table 2) . The difference between squamous and non-squamous histology failed to find a significant association with fatal hemoptysis. However, the 
Discussion
A Phase I trial found that CCRT was tolerable under the maximal tolerated dose without reporting a fatal toxicity, such as fatal hemoptysis, which can lead to sudden death. 7 In our retrospective review of CCRT in locally In addition, pulmonary infection may be linked to fatal hemoptysis for 6 out of 12 patients with pulmonary infection prior to fatal hemoptysis, as presented in Table 1 . At present, no clinical trial has supported one specific agent over others in the setting of CCRT. 6, [19] [20] [21] [22] In this study, gemcitabine had mixed results according to to both univariate and multivariate analyses. The relatively small number and uneven distribution of chemotherapeutics in patients with fatal hemoptysis might be a limitation of statistical power to support the result. We found only one case report about gemcitabine-associated diffuse alveolar hemorrhage in the literature. 23 We looked for common radiologic findings in patients with fatal hemoptysis.
However, chest CT scan findings in patients who died of fatal hemoptysis varied from cavitary changes and concentric bronchial wall thickening to various types of radiation injury, because three-dimensional conformal radiation therapy can result in an unusual distribution of findings. 21 We think that further studies on radiologic findings, in addition to the correlation of chemotherapeutic agents with toxicity following CCRT, would be required. Fatal hemoptysis after CCRT in advanced NSCLC patients can happen unexpectedly and culminate in a fatal consequence. Hence, when we consider CCRT in patients with centrally located NSCLC, especially when performance status is not good, we should take into account the possibility of fatal hemoptysis.
